Bristol-Myers Denial of Deal Sends Amgen Stock Tumbling
NEW YORK — Amgen Inc. shares tumbled Thursday after Bristol-Myers Squibb Co. denied rumors that it is in talks to acquire the biotechnology company.
“Bristol-Myers Squibb is not and has not been in any discussions with Amgen regarding the acquisition of the company,” the New York-based drug company said in a statement.
Bristol-Myers said it broke with its policy of not commenting on rumors because “the persistent and widespread speculation on Bristol-Myers Squibb and Amgen should be laid to rest.”
Thousand Oaks-based Amgen closed down $4 at $66.75 on Nasdaq after falling as much as $4.75 earlier in the day, following Bristol-Myers’ announcement.
On Wednesday, Amgen had soared $5.375 as speculation intensified that the company might soon be acquired by Bristol-Myers for $90 a share.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
